Home>Video>Healthcare Winners and Losers From Obamacare Repeal

Healthcare Winners and Losers From Obamacare Repeal

Mon, 21 Nov 2016

The potential repeal of the Affordable Care Act will hurt hospitals, but we think some wide-moat pharma and biotech companies should be able to withstand the turbulence.


Video Transcript

Debbie Wang: With the Trump administration and Republican control of Congress, we think they are going to make an early attempt at dismantling key pieces of the Affordable Care Act. This will end up translating into more people being uninsured. We see this as a negative for hospitals because they will have more patients coming in who are uninsured, and that will drive up bad debt expense. We see this as a positive for pharma and biotech because they will no longer have to pay in the ACA-required fees which were used to help subsidize premiums for the lower-income insureds. And we see this as a mixed bag for managed care companies, in that they will now be able to pull out of the insurance exchanges that are not profitable, but on the other hand, they will probably still be required to write insurance for insureds who come in with a pre-existing condition.

For investors, we continue to look for companies in healthcare that have moats. So, companies like Johnson & Johnson or Pfizer or Medtronic that have wide economic moats are the ones that we think are most likely to be able to withstand the turbulence that we will probably be seeing in the near term.

  1. Related Videos
  2. Related Articles
  1. Undervalued Pfizer Offers Great Dividend Opportunity

    Morningstar's Damien Conover expects steady growth for the wide-moat firm, which will likely lead to steady growth for the dividend.

  2. Super-Wide Moat in the Making at Medtronic

    The device maker's planned acquisition of Covidien will make it a force to be reckoned with.

  3. 2 Undervalued Biotechs Vying for a Big Market

    Gilead and Intercept are both developing drugs aimed at a $10 billion market opportunity in liver-disease treatment, but they present different considerations for biotech investors.

  4. This Healthy Drugmaker Is Undervalued

    We think the market is underestimating wide-moat Biogen's potential to expand its neurology portfolio beyond multiple sclerosis.

  5. Why Moats Matter

    An economic moat provides a gauge of a company's competitive advantages and overall strength, and it is a highly valuable tool for investors of all levels.

  6. A Rare Time for Wide-Moat Stocks?

    StockInvestor editor Paul Larson details recent changes to Morningstar's Wide Moat Focus Index, noting how the rally in wide-moat names could have them more fairly priced than lower-quality stocks.

  7. 3 Stock Picks in the Oil-Services Sector

    The increasing complexity and capital intensity of oil and gas drilling creates significant long-term potential for these undervalued wide-moat companies, says Morningstar's Rob Bellinski.

  8. 5 Wide-Moat Stocks That Were Left Behind in 2014

    It was a good year for wide-moat stocks overall, but Exxon, Amazon, and a few others lagged the market, says Morningstar markets editor Jeremy Glaser.

©2017 Morningstar Advisor. All right reserved.